Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan;58(1):81-91.
doi: 10.1007/s00592-020-01581-x. Epub 2020 Aug 30.

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

Sidar Copur  1 , Dimitrie Siriopol  2 , Baris Afsar  3 , Melis C Comert  1 , Gizem Uzunkopru  1 , Alan A Sag  4 , Alberto Ortiz  5 , Adrian Covic  2 , Daniel H van Raalte  6 , David Z Cherney  7   8 , Peter Rossing  9 , Mehmet Kanbay  10
Affiliations
Meta-Analysis

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

Sidar Copur et al. Acta Diabetol. 2021 Jan.

Abstract

Background and aim: HbA1c, the traditional and current gold standard biomarker guiding diabetic management, has been scrutinized for low predictive value for patients with chronic kidney disease due to variables affecting erythrocyte number and turnover. Glycated albumin, the precursor to advanced glycation end products, reflects glycemic status over the preceding 2-3 week period and already outperforms HbA1c for glycemic monitoring. Our aim was to establish whether serum GA can be further used to predict mortality risk in dialysis patients with diabetes mellitus (DM) METHODS: We did systematic review of the literature in PubMed/Medline, Web of Science, Embase (Elsevier) and the Cochrane Central Register of Controlled Trials (Wiley) up to and including February 2020.

Results: This meta-analysis included 25,932 dialysis patients across 12 studies with maximum follow-up of 11 years. Higher GA levels were associated with the risk of all-cause mortality in dialysis patients with DM (HR 1.02, 95% CI 1.01 to 1.03, P < 0.001) irrespective of the type of dialysis, whereas higher GA was not associated with cardiovascular mortality (HR 1.03, 95% CI 0.99 to 1.06, P = 0.15) and cardiovascular events (both fatal and non-fatal) (HR 1.03, 95% CI 0.97 to 1.09, P = 0.31) in dialysis patients with DM.

Conclusion: Serum glycated albumin predicts all-cause mortality risk in dialysis patients with DM. The endpoints of cardiovascular mortality and cardiovascular events trended similarly, but did not reach significance at the current sample size.

Keywords: Cardiovascular mortality; Chronic kidney disease; Diabetes mellitus; Dialysis; Glycated albumin.

PubMed Disclaimer

References

References:

    1. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS et al (2016) Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 165(7):473–481 - PubMed - PMC
    1. Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F et al (2016) Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 4(4):360–373 - PubMed
    1. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM (2006) Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70(8):1503–1509 - PubMed
    1. Standards of medical care in diabetes (2015) summary of revisions. Diabetes Care. 38(Suppl):S4
    1. National KF (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886

MeSH terms

LinkOut - more resources